Series E Financing Reflects Sustained Investor Confidence in CeQur's Commercial Trajectory, Clinical Results, and Growing Demand for a Simpler Approach to Mealtime Insulin

E轮融资彰显了投资者对CeQur商业化进程、临床成果以及市场对更简便餐时胰岛素方案日益增长的需求的持续信心

HORW, Switzerland

瑞士霍尔韦

,

，

June 9, 2026

2026年6月9日

/PRNewswire/ --

/美通社/ --

CeQur

CeQur

, the company dedicated to simplifying mealtime insulin delivery for people living with diabetes, today announced the close of a $100 million Series E financing round. The investment reflects sustained investor confidence in CeQur's commercial trajectory, its strong pipeline, and the growing demand for a simpler approach to mealtime insulin.

致力于简化糖尿病患者餐时胰岛素递送的公司CeQur今日宣布完成1亿美元的E轮融资。此次投资反映了投资者对CeQur商业化路径、其强劲的产品管线以及对更简便的餐时胰岛素方案日益增长的需求的持续信心。

The Series E reflects CeQur's momentum and marks the beginning of its most ambitious phase of commercial growth..

E轮融资体现了CeQur的发展势头，并标志着其最具雄心的商业增长阶段的开启。

Continue Reading

继续阅读

CeQur Simplicity™ Mealtime Insulin Patch

CeQur Simplicity™ 餐时胰岛素贴片

The $100 million will accelerate growth across every dimension of the commercial operation, and CeQur has the infrastructure to deploy it. The field sales team will expand, deepening relationships with healthcare providers and diabetes care specialists who are looking for a simpler approach to mealtime insulin for their patients.

这笔1亿美元的资金将加速商业运营在各个维度的增长，而CeQur拥有部署该资金所需的基础设施。现场销售团队将扩大规模，进一步深化与医疗保健提供者和糖尿病护理专家的合作关系，这些专业人士正为其患者寻求更简便的餐时胰岛素治疗方案。

As CeQur Simplicity expands to include extended 7-day wear and both 1-unit and 2-unit options, the company is positioned to meet demand across a broader and growing patient population..

随着 CeQur Simplicity 产品线扩展至涵盖长达7天的佩戴期，并提供单单元和双单元两种选项，该公司已做好准备，以满足更广泛且不断增长的病患群体的需求。

'We have the commercial infrastructure, new clinical evidence. and an exciting pipeline. Now we have the capital to accelerate our growth,'

“我们拥有商业基础设施、最新的临床证据以及令人振奋的产品管线。如今，我们已具备资本来加速我们的增长。”

said

说

Bradley Paddock, President and Chief Executive Officer of CeQur.

CeQur 公司总裁兼首席执行官布拉德利·帕多克。

'CeQur Simplicity is ready to reach every patient and physician who wants to simplify their insulin delivery and improve their diabetes management.'

CeQur Simplicity 已准备好服务于每一位希望简化胰岛素给药并改善糖尿病管理的患者和医生。

Adoption of CeQur Simplicity is expanding steadily across primary care and endocrinology practices nationwide. Better than 85% of all claims are covered as a pharmacy benefit, with an average copay of less than $45 per month. Clinically, the evidence is equally compelling: nearly 90% of patients reported following their insulin regimen better with CeQur Simplicity.

CeQur Simplicity 在全国初级保健和内分泌科诊所中的应用正稳步扩大。超过 85% 的索赔作为药房福利获得承保，平均每月自付费用低于 45 美元。在临床方面，证据同样有力：近 90% 的患者报告称，使用 CeQur Simplicity 后能更好地遵循其胰岛素治疗方案。

1

1

compared to multiple daily injections, with significantly improved A1C

与每日多次注射相比，糖化血红蛋白（A1C）显著改善

2

2

and time-in-range outcomes

以及血糖达标时间结果

3

3

.

。

'This financing is a direct reflection of what the CeQur team has built and the confidence our investors have placed in CeQur's growth trajectory,'

“此次融资直接反映了CeQur团队所取得的成果，以及投资者对CeQur增长轨迹的信心。”

said

说

Mike Rubino, Chief Financial Officer of CeQur.

CeQur 首席财务官 Mike Rubino。

'We are grateful for that trust and committed to deploying this capital to deliver on the full potential of CeQur Simplicity for patients, for providers, and for every investor who believes in our mission.'

“我们感谢这份信任，并致力于部署这笔资金，以充分实现 CeQur Simplicity 为患者、医疗服务提供者以及每一位相信我们使命的投资者带来的全部潜力。”

With

与

new FDA clearances

新的FDA批准

, compelling clinical data, and $100 million in capital, CeQur Simplicity is positioned to ensure that patients who want a simpler approach to insulin delivery have options.

凭借令人信服的临床数据和1亿美元资本，CeQur Simplicity致力于确保希望采用更简便胰岛素给药方式的患者拥有更多选择。

About CeQur Simplicity

关于 CeQur Simplicity

™

™

CeQur Simplicity is a convenient, discreet, and injection-free wearable insulin patch that simplifies mealtime dosing. The patch is clinically proven to improve glycemic control, with patients achieving significantly improved A1C

CeQur Simplicity 是一款方便、隐蔽且无需注射的可穿戴胰岛素贴片，可简化餐时剂量给药。临床证明，该贴片能改善血糖控制，使患者的糖化血红蛋白（A1C）水平显著降低。

2

2

and time-in-range goals

以及目标范围内时间（TIR）目标

3

3

. For people over 21 years of age with diabetes.

适用于21岁以上的糖尿病患者。

Learn more at

了解更多，请访问

MyCeQurSimplicity.com

MyCeQurSimplicity.com

or call 1-888-55-CEQUR.

或拨打 1-888-55-CEQUR。

About CeQur

关于 CeQur

®

®

CeQur commercializes advanced, simple-to-use insulin-delivery devices that make it easier for people living with diabetes to adhere to therapy and stay in control of their disease. The Company's simple, wearable devices provide freedom from multiple daily insulin injections.

CeQur 公司商业化推广先进且易于使用的胰岛素输送装置，使糖尿病患者更容易坚持治疗并有效控制病情。该公司提供的简易可穿戴设备让患者免于每日多次注射胰岛素。

Zraick V, Dreon D, Nalk R, Shearer D, Crawford S, Bradford J, Levy B. Patient User Experience Evaluation of Bolus Patch Insulin Delivery System. Poster presented at: American Diabetes Association 76th Scientific Sessions; 2016; New Orleans, LA. Abstract 995-P.

Zraick V, Dreon D, Nalk R, Shearer D, Crawford S, Bradford J, Levy B. 患者对推注贴片胰岛素给药系统的用户体验评估。海报展示于：美国糖尿病协会第76届科学会议；2016年；路易斯安那州新奥尔良。摘要995-P。

Bergenstal R, Peyrot M, Dreon D, Aroda V, Bailey T, Brazg R, Frias J, Johnson M, Klonoff D, Kruger D, Ramtoola S, Rosenstock J, Serusclat P, Weinstock R, Naik R, Shearer D, Zraick V, Levy B. 2019. Implementation of Basal–Bolus Therapy in Type 2 Diabetes: A Randomized Controlled Trial Comparing Bolus Insulin Delivery Using an Insulin Patch with an Insulin Pen.

Bergenstal R, Peyrot M, Dreon D, Aroda V, Bailey T, Brazg R, Frias J, Johnson M, Klonoff D, Kruger D, Ramtoola S, Rosenstock J, Serusclat P, Weinstock R, Naik R, Shearer D, Zraick V, Levy B. 2019. 在2型糖尿病中实施基础-餐时疗法：一项比较使用胰岛素贴与胰岛素笔进行餐时胰岛素给药的随机对照试验。

Diabetes Technology and Therapeutics 21 (5):1-13..

《糖尿病技术与治疗》21(5):1-13。

Bergenstal R., et al Comparing Patch vs Pen Bolus Insulin Delivery in Type 2 Diabetes Using Continuous Glucose Monitoring Metrics and Profiles; Journal of Diabetes Science and Technology 1–7, 2021

Bergenstal R. 等人，使用连续血糖监测指标和图谱比较2型糖尿病中贴片式与笔式推注胰岛素的给药方式；《糖尿病科学与技术杂志》1–7页，2021年

SOURCE CeQur Corporation

来源：CeQur 公司

21

二十一

%

%

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示